REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss financial results for the quarter ended June 30, 2026, and operational highlights. Webcast registration links are provided for listeners and analysts, with a replay available on the investor website about two hours after the call.

Market Context

The scheduled second-quarter results call follows a tag-matched record that included a 5.57% 24-hour...

Analysis

The scheduled second-quarter results call follows a tag-matched record that included a 5.57% 24-hour reaction. Moderate short positioning and Net Selling insider sentiment add risk context; watch the disclosed financial results and operational highlights.

Key Figures

Reporting period: Second quarter 2026 Quarter end: June 30, 2026 Conference call date: August 6 +4 more

7 metrics

Reporting period Second quarter 2026 Financial results to be discussed

Quarter end June 30, 2026 End of reporting period

Conference call date August 6 Scheduled results call

Conference call time 8:00 a.m. ET Scheduled start time

Replay availability Approximately two hours After the call's conclusion

Recommended early arrival 15 minutes Before the scheduled start time

Company founding 2009 REGENXBIO founding year

Previous Conferences,earnings date Reports

5 past events · Latest: Feb 25 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Conference call	Positive	+5.6%	Scheduled fourth-quarter and full-year 2025 results call; shares rose 5.57% afterward.
Oct 29	Conference call	Negative	-2.4%	Scheduled third-quarter 2025 results call; shares fell 2.43% during the following 24 hours.
Jul 31	Conference call	Negative	-2.7%	Scheduled second-quarter 2025 results call; shares fell 2.74% afterward.
Apr 30	Conference call	Positive	+2.3%	Scheduled first-quarter 2025 results call; shares rose 2.29% afterward.
Feb 26	Conference call	Negative	-1.1%	Scheduled fourth-quarter and full-year 2024 results call; shares fell 1.05% afterward.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-matched conference-call announcements produced mixed reactions, with two positive and three negative 24-hour moves.

Key Terms

aav, mps ii, wet amd, diabetic retinopathy

4 terms

aav medical

"REGENXBIO has pioneered the field of AAV gene therapy."

AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.

mps ii medical

"NAVSUNLI™ ... for the treatment of MPS II"

A rare, inherited metabolic disorder also known as Hunter syndrome, caused by a missing or nonworking enzyme that normally breaks down long-chain sugar molecules; this leads to progressive buildup of materials in cells and damage to organs, tissues and sometimes the brain. It matters to investors because developing, testing, and approving treatments for MPS II involves specialized clinical trials, regulatory incentives and potentially high-value orphan-drug markets, so trial results, approvals, or setbacks can materially affect companies working in this area.

wet amd medical

"surabgene lomparvovec ... for the treatment of wet AMD"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

diabetic retinopathy medical

"surabgene lomparvovec ... for the treatment of ... diabetic retinopathy"

Diabetic retinopathy is an eye disease where prolonged high blood sugar damages the tiny blood vessels and nerve tissue at the back of the eye, leading to blurred vision or blindness if untreated. Investors track it because the condition affects a large, growing patient population and drives demand for screening tools, drugs, surgical devices and long-term care—think of it like damaged wiring in a camera that creates a market for repairs and upgrades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-6-to-discuss-second-quarter-2026-financial-results-and-operational-highlights-302840354.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) reporting second quarter 2026 financial results?

REGENXBIO will discuss its second quarter 2026 financial results on a conference call on Thursday, August 6, at 8:00 a.m. ET. According to REGENXBIO, the call will also cover operational highlights for the quarter ended June 30, 2026.

How can investors listen to the REGENXBIO (RGNX) Q2 2026 earnings conference call?

Investors can listen via a webcast by registering through the provided listener link. According to REGENXBIO, a separate registration link is available for analysts wishing to participate in the question-and-answer session during the August 6, 2026 conference call.

Will a replay be available for the REGENXBIO (RGNX) August 6, 2026 earnings call?

Yes, a replay of the webcast will be available on REGENXBIO’s investor website. According to REGENXBIO, the replay will be posted approximately two hours after the conference call concludes, allowing investors to review financial results and operational highlights later.

What time should participants join the REGENXBIO (RGNX) Q2 2026 conference call?

Participants are advised to join the conference call about 15 minutes before the 8:00 a.m. ET start time. According to REGENXBIO, early login on August 6 helps ensure successful access to the webcast and any required registration steps.

What topics will REGENXBIO (RGNX) cover on the August 6, 2026 conference call?

The conference call will cover financial results for the second quarter ended June 30, 2026, and operational highlights. According to REGENXBIO, this includes updates relevant to its biotechnology operations and gene therapy pipeline progress during the period.